Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Dmitry Osipov will leave the position of VSMPO-AVISMA General Director

4/3/23 VSMO

First line of Arctic LNG-2 is 95% ready

4/3/23 NVTK

Kaluga Sales Company reported for 2022 according to RAS

4/3/23 KLSB

Himprom's 2022 RAS profit quadrupled

4/3/23 HIMCP

Abrau-Durso reported for 2022 according to RAS

4/3/23 ABRD

MGTS reported for 2022 according to RAS

4/3/23 MGTS

In RuStore appeared foreign applications

4/3/23 VKCO

Rosneft discovered new hydrocarbon deposits in the Chechen Republic

4/3/23 ROSN

Profit of Mother and Child in 2022 decreased by 23.2%

4/3/23 MDMG

Rostelecom gets 51% in public Wi-Fi provider MaximaTelecom

4/3/23 RTKM